Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

87.5%

7 terminated/withdrawn out of 8 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
5(71.4%)
Phase 4
2(28.6%)
7Total
N/A(5)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT01817543Not ApplicableTerminated

A Cohort Trial Comparing AutoloGel Therapy to Usual and Customary Care in Venous Leg Ulcers

Role: lead

NCT01816633Not ApplicableTerminated

Effectiveness of AutoloGel Therapy in Diabetic Foot Ulcers

Role: lead

NCT02248077Phase 4Withdrawn

A Prospective, Randomized, Controlled, Multi-Center, Study Evaluating AutoloGel Therapy for Complete Closure of Wagner Grade 1-4 Diabetic Foot Ulcers, Venous Leg Ulcers and Stage II-IV Pressure Ulcers

Role: lead

NCT01819142Not ApplicableTerminated

AutoloGel Therapy to Usual and Customary Care in Pressure Ulcers

Role: lead

NCT02940587Phase 4Withdrawn

Effectiveness of Aurix Therapy in Venous Leg Ulcers

Role: lead

NCT01816672Not ApplicableTerminated

Efficacy of AutoloGel Therapy to Usual and Customary Care in Wagner gd 1 and 2 Diabetic Foot Ulcers.

Role: lead

NCT00762138Not ApplicableTerminated

The AutoloGel™ Post-Market Surveillance (TAPS) Program

Role: lead

NCT01740908Unknown

Stem Cell Quantification In Peripheral Blood After Hyperbaric Oxygen Therapy Treatments

Role: collaborator

All 8 trials loaded